Cell division

Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience

Retrieved on: 
Wednesday, August 16, 2023
VRK1, Cell division, DNA, Cancer, VRK2, Head, Research, Patient, Neoplasm, Pharmaceutical industry

BRISBANE, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it has entered into an exclusive, worldwide license agreement and research collaboration with Sprint Bioscience for its VRK1 program.

Key Points: 
  • BRISBANE, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it has entered into an exclusive, worldwide license agreement and research collaboration with Sprint Bioscience for its VRK1 program.
  • Vaccinia-related kinase 1 (VRK1) is a novel target involved in the regulation of cell division and DNA damage repair.
  • “We look forward to collaborating with Sprint Bioscience, who has strong discovery and research expertise, and working to advance the VRK1 program through lead optimization and into the clinic.”
    Under the terms of the agreement, Day One will make an upfront payment of $3 million to Sprint Bioscience and reimburse Sprint Bioscience for pre-clinical research and development expenses.
  • Sprint Bioscience will be eligible to receive additional milestone payments of up to approximately $313 million plus single-digit royalties pending achievement of certain research, development, regulatory and commercial outcomes.

Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel

Retrieved on: 
Tuesday, August 8, 2023
Reflex, Laboratory, Workflow, CML, EMR, BCR, Mutation, BCR-ABL, Cell, Electronic health record, Point mutation, Patient, Cell division, LIS, Diagnosis, Health, ABL1, Economics, Chronic myelogenous leukemia, Medical device, HAVEN

NEW HAVEN, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces the launch of its new quantitative BCR-ABL 2.0 panel, with features making it the most innovative panel of its kind on the market.

Key Points: 
  • NEW HAVEN, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces the launch of its new quantitative BCR-ABL 2.0 panel, with features making it the most innovative panel of its kind on the market.
  • For more information on this new panel please visit us at https://tinyurl.com/QBCR-ABL1 .
  • The following features make this product the most advanced BCR-ABL panel on the market, besting competition in terms of robust coverage, workflow ease, accuracy, and cost:
    1.
  • Precipio’s HemeScreen BCR-ABL 2.0 assay is the only panel on the market that provides quantitative coverage of four clinically relevant2,3 breakpoints – p.190, p.210, p.203 and p.230.

Groundbreaking Results Using Canady Helios™ Cold Plasma Treatment Published in MDPI Journal “Cancers”

Retrieved on: 
Wednesday, August 2, 2023
Research, Technology, Medical Devices, Surgery, Health Technology, Biotechnology, Robotics, Health, Science, Oncology, Canady, Cell death, RNS, Histone, Survival, Clinical trial, Immunotherapy, CHCP, Irreversible electroporation, Plasma, ROS, Cancer, LRR, Patient, Sheba Medical Center, Reactive oxygen species, Apoptosis, Education minister, Cell division, FACS, Neoplasm, Rush University Medical Center, Recurrence, FDA, Reactive nitrogen species, Messenger, Pharmaceutical industry

It is estimated that 65% of solid tumor resections result in residual microscopic tumor cells at the surgical margin, which contributes to LRR and poor survival rates.

Key Points: 
  • It is estimated that 65% of solid tumor resections result in residual microscopic tumor cells at the surgical margin, which contributes to LRR and poor survival rates.
  • The recent trial reveals that treating the surgical margin following a tumorectomy significantly reduced local recurrence and increased overall survival.
  • CHCP opens a new and promising treatment for addressing the challenges of eradicating microscopic residual cancer cells following surgical tumor resection.
  • Jerome Canady, M.D., FACS, CEO stated, “We are very pleased to have our results published in the peer reviewed journal 'Cancers'.

Zooming across time and space simultaneously with superresolution to understand how cells divide

Retrieved on: 
Thursday, July 20, 2023
Tissue, Nobel Prize, DNA, Cell division, University, Protein, Cancer, Light, Polymer, Liquid, Cell, Biology, PINE, Behavior, Disease, Fine chemical, Microscope, Medical imaging

Every cell inherits the same protein and DNA building blocks that make up the cell it originally came from.

Key Points: 
  • Every cell inherits the same protein and DNA building blocks that make up the cell it originally came from.
  • Yet exactly how these molecular building blocks arrange themselves into new cells has remained a mystery.

Advancing superresolution imaging

    • It wasn’t possible to view cells at the molecular level until recently with the 2014 Nobel Prize-winning development of superresolution.
    • With superresolution, fluorescent probes attached to the sample could be switched on and off like twinkling stars on a clear night.
    • By collecting and combining many images of these probes, a superresolution image can bring very small objects into view.

Shedding new light on cell division

    • We made three observations on how actin building blocks organize during cell division.
    • Based on these findings, we were able to discover new information about the process of cell division.
    • We found that interactions between actin building blocks sync up with the contraction and expansion of the whole cell during division.

Uncovering disease with superresolution

    • We also plan to use our imaging technique to study how protein building blocks become disorganized in disease.
    • Our technique could potentially help researchers visualize and, in turn, better understand how molecular defects in tissues and organs may develop into disease.

OnQuality Announces FDA Clearance of IND Application for OQL051, for the Prophylaxis of Chemotherapy-Induced Diarrhea

Retrieved on: 
Wednesday, June 7, 2023
Infection, Drug development, Gastrointestinal tract, Hospital, Malnutrition, Dehydration, FACP, Skin, Cancer, Quality of life, Toxicity, MD, Patient, CID, Cell division, FDA, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, G1 phase, Food, Safety, Pharmaceutical industry

CID is a common and often debilitating toxicity affecting up to 90% of patients receiving chemotherapy.

Key Points: 
  • CID is a common and often debilitating toxicity affecting up to 90% of patients receiving chemotherapy.
  • CID can cause dehydration, electrolyte imbalance, malnutrition, and infection, which may lead to hospitalization, cardiovascular compromise, and in some cases death.
  • Treatment of CID may require interruption or even permanent discontinuation of chemotherapy, and potentially compromising the effectiveness of cancer therapy.
  • This is a significant milestone for OnQuality and for patients suffering from CID," said Hong Tang, MD, FACP, Chief Medical Officer at OnQuality.

Trethera Receives $2 Million National Cancer Institute Grant for Advancement of Clinically Relevant Biomarkers in Phase 1 Trial

Retrieved on: 
Tuesday, May 30, 2023
Surgical oncology, Drug development, SBIR, Small Business Innovation Research, Cancer, Cell proliferation, Biomarker, National Cancer Institute, HIV disease progression rates, Patient, Cell division, Lymphocyte, UCLA, NCI, Safety, Disease, Pharmaceutical industry, Urology

The grant will fund additional patient dosing studies to identify predictive biomarkers of activity and target engagement of TRE-515 in solid tumors.

Key Points: 
  • The grant will fund additional patient dosing studies to identify predictive biomarkers of activity and target engagement of TRE-515 in solid tumors.
  • "We are honored to receive this highly competitive SBIR grant that supports additional clinical advancement and compelling opportunities for TRE-515," said Dr. Ken Schultz, principal investigator and Trethera CEO.
  • "This grant allows further biomarker evaluations, helping to inform patient selection and dosing in order to target multiple types of difficult to treat cancers."
  • The NCI grant follows favorable results announced earlier this year from Trethera’s Phase 1a clinical trial in high risk, heavily pretreated patients with solid tumor malignancies.

Live Cell Imaging Market worth $4.3 billion | MarketsandMarkets

Retrieved on: 
Tuesday, May 30, 2023
Omni, GE HealthCare, Prevalence, FRAP, Merck Group, Olympus Corporation, Genetics, Data analysis, Neuroscience, Conditional sentence, PHI, Automation, Biomedical Research, Research, Gene expression, Photobleaching, Drug discovery, Developmental biology, Cell division, Growth, Wireless power transfer, BD, Cell biology, Corning Inc., Cancer, Cell, Government, Participation, HCS, Agilent Technologies, Eliot Porter, B cell, AX, Bruker, DSM-IV codes, Sartorius AG, Temporal, PerkinElmer, Nikon, FRET, Pharmacology, Imaging, Microscope, Pharmaceutical industry, Fine chemical, Medical imaging, Mobile phone, Retail, Cytoskeleton

The live cell imaging market in North America has experienced significant growth in recent years, showcasing a robust expansion trajectory, owing to the well-established research infrastructure, strong pharmaceutical and biotech industry, increasing government support for life science research, technological advancements in live cell imaging, and collaborative initiatives contribute to the growth of the live cell imaging market in the North America region.

Key Points: 
  • The live cell imaging market in North America has experienced significant growth in recent years, showcasing a robust expansion trajectory, owing to the well-established research infrastructure, strong pharmaceutical and biotech industry, increasing government support for life science research, technological advancements in live cell imaging, and collaborative initiatives contribute to the growth of the live cell imaging market in the North America region.
  • Live Cell Imaging Market Advantages:
    Real-Time Visualization: Live cell imaging allows researchers to observe and analyze cellular processes in real time, providing dynamic and detailed insights into cellular behavior.
  • Advancements in Imaging Technologies: The live cell imaging market benefits from continuous advancements in imaging technologies, including improved microscope systems, sensitive detectors, and fluorophores.
  • Live Cell Imaging market - Report Highlights:
    The market size is updated for the base year 2022 and forecasted from 2023 to 2028 by studying the impact of the recession on the overall live cell imaging industry.

Live Cell Imaging Market worth $4.3 billion | MarketsandMarkets

Retrieved on: 
Tuesday, May 30, 2023
Omni, GE HealthCare, Prevalence, FRAP, Merck Group, Olympus Corporation, Genetics, Data analysis, Neuroscience, Conditional sentence, PHI, Automation, Biomedical Research, Research, Gene expression, Photobleaching, Drug discovery, Developmental biology, Cell division, Growth, Wireless power transfer, BD, Cell biology, Corning Inc., Cancer, Cell, Government, Participation, HCS, Agilent Technologies, Eliot Porter, B cell, AX, Bruker, DSM-IV codes, Sartorius AG, Temporal, PerkinElmer, Nikon, FRET, Pharmacology, Imaging, Microscope, Pharmaceutical industry, Fine chemical, Medical imaging, Mobile phone, Retail, Cytoskeleton

The live cell imaging market in North America has experienced significant growth in recent years, showcasing a robust expansion trajectory, owing to the well-established research infrastructure, strong pharmaceutical and biotech industry, increasing government support for life science research, technological advancements in live cell imaging, and collaborative initiatives contribute to the growth of the live cell imaging market in the North America region.

Key Points: 
  • The live cell imaging market in North America has experienced significant growth in recent years, showcasing a robust expansion trajectory, owing to the well-established research infrastructure, strong pharmaceutical and biotech industry, increasing government support for life science research, technological advancements in live cell imaging, and collaborative initiatives contribute to the growth of the live cell imaging market in the North America region.
  • Live Cell Imaging Market Advantages:
    Real-Time Visualization: Live cell imaging allows researchers to observe and analyze cellular processes in real time, providing dynamic and detailed insights into cellular behavior.
  • Advancements in Imaging Technologies: The live cell imaging market benefits from continuous advancements in imaging technologies, including improved microscope systems, sensitive detectors, and fluorophores.
  • Live Cell Imaging market - Report Highlights:
    The market size is updated for the base year 2022 and forecasted from 2023 to 2028 by studying the impact of the recession on the overall live cell imaging industry.

Stowers Institute scientists discover the dynamics of an "extra" chromosome in fruit flies, offers unique opportunity to study similar chromosomes linked to cancer and infertility in humans

Retrieved on: 
Thursday, May 4, 2023
University, Medicine, Human, Stowers Institute for Medical Research, Neoplasm, Drosophila melanogaster, Meiosis, Osteosarcoma, Infertility, Research, Hanlon, Fruit, Bangladesh Technical Education Board, Current Biology, Chromosome, Achilles, Cancer, Cell division, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Medical research, NIH, Biology, Genome, Dietary supplement, Antibiotics

Now, researchers from the Stowers Institute for Medical Research have revealed the dynamics of a new, very young chromosome in fruit flies that is similar to chromosomes that arise in humans and is associated with treatment-resistant cancer and infertility.

Key Points: 
  • Now, researchers from the Stowers Institute for Medical Research have revealed the dynamics of a new, very young chromosome in fruit flies that is similar to chromosomes that arise in humans and is associated with treatment-resistant cancer and infertility.
  • Previous research from the Hawley Lab had first identified these small, extra chromosomes, but little was known about their form, function, or dynamics during cell division.
  • In addition, the presence of supernumerary chromosomes in men can disrupt normal chromosome segregation during sperm production, which can cause infertility.
  • "Being able to understand how supernumerary chromosomes arise and what their structures are can potentially illuminate their vulnerabilities," said Hawley.

Monteloeder by Suanfarma: New Clinical Study Finds Powerful Anti-Aging Benefits in Four-Botanical Blend

Retrieved on: 
Wednesday, April 12, 2023
Immortalised cell line, Tissue, Elasticity, Pollution, DNA, Citrus, Diet, Skin care, Telomere, Elastin, Skin, Ageing, Glycation, Woman, Research, Cell, Pigment, Doctor of Philosophy, Trial of the century, Centella, Punica, Polyphenol, Beauty, Oxidative stress, Cosmetics, Cell division, Collagen, Flavones, Dry, Longevity, Human, Fatigue, Medicinal plants, Dietary supplement

MADRID, April 12, 2023 /PRNewswire/ -- A new clinical study supports powerful anti-aging skin benefits of Eternalyoung®, a blend of four botanical ingredients from Monteloeder, S. L., a subsidiary of Suanfarma. Eternalyoung is the result of extensive research and contains several polyphenols that work synergistically to provide anti-aging benefits for the skin.

Key Points: 
  • Polyphenol-rich blend of botanicals from Suanfarma, shown to preserve telomeres:- the body's primary skin rejuvenator
    MADRID, April 12, 2023 /PRNewswire/ -- A new clinical study supports powerful anti-aging skin benefits of Eternalyoung®, a blend of four botanical ingredients from Monteloeder, S. L., a subsidiary of Suanfarma .
  • Eternalyoung is the result of extensive research and contains several polyphenols that work synergistically to provide anti-aging benefits for the skin.
  • The botanical blend intervention visibly and structurally improved the skin and reduced signs of aging, without side effects.
  • Subjectively, subjects who consumed the botanical blend reported that their skin felt more "radiant, healthy, and youthful."